In this short and engaging episode of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) share their take on the most impactful hot-line and late-breaking trials from ESC 2022. 

Which trials should we look out for?

Trials covered in detail include:
TAILOR-PCI: Tailored Antiplatelet Therapy Following PCI 
ASCEND: A Study of Cardiovascular Events iN Diabetes 
REDUCE-IT: A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin 
COAPT: Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation 
PHYSIC: The Precision Hypertension Care Study 
EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction) 
RIVER: RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial 
REVIVED-BCIS2: Study of Efficacy and Safety of Percutaneous Coronary Intervention to Improve Survival in Heart Failure 
PACIFIC-AMI: Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack 
AI-ENHANCED: Enhanced Diagnosis of Severe Aortic Stenosis Using Artificial Intelligence: A Proof-of-Concept Study of 530,871 Echocardiograms 
PREFFIR: Prediction of Recurrent Events With 18F-Fluoride
FRAME-AMI: FFR Versus Angiography-Guided Strategy for Management of AMI With Multivessel Disease 
PANTHER: P2Y12 inhibitor or Aspirin moNoTHERapy as secondary prevention in patients with coronary artery disease: in individual patient data meta-analysis